The objective of a family cord blood bank is to process and cryopreserve cord blood units (CBUs) that may be used for hemapoietic stem cell transplantation or for future use through regenerative medicine therapies (Armson et al. 2005).
Clinical outcomes of cord blood (CB) transplantation are influenced by the number of total nucleated cells (TNCs) in a CBU (Mazzocchetii et al 2014). Hence, it is important to obtain a large volume of CB during collection and maximize the retrieval of TNCs during processing to increase the quality of the unit (Gluckman et al 2004, Barker et al 2010, Jaime-Perez 2011 & Mazzocchetti 2014).
Furthermore, extensive research and clinical analysis have supported that, “the most important factor for the selection of a CBU for hematopoietic (blood-forming) stem cell transplantation is the TNC count which is used as a surrogate marker for stem cell content in a CBU.” (Manegold-Brauer et al 2014).
Transparency, superior quality, significant results and processing innovation are all key attributes endorsed in Progenics newly released Monthly Quality Report. This quality report provides a detailed summary and analysis of the processing results from all of the cord blood samples processed by Progenics Cord Blood Cryobank from January 1, 2013 to December 31, 2016. The quality indicators referenced in the report look at 3 key variables: The yield of total nucleated cells (TNC); total viable nucleated cells (TVNC), and; CD34+ viability.
From 2013 to 2016 the report highlights the following annual averages:
- The average annual percentage yield of total nucleated cells (TNC) was 98.22%
- The average annual percentage of total viable nucleated cells (TVNC) was 93.59%
- The average annual percentage of viable CD34+ cells was 99.13%
Significantly, the Progenics quality report results indicate that the outcome of the quality processing surpasses our internal quality standard by over 10%! Supported by the data published in our quality report, at Progenics Cord Blood Cryobank, we can confidently claim that clients are receiving the highest cord blood processing results in the industry.Take a look at our Quality Report
Armson, BA, Allan, DS & Casper, R, 2005, ‘Umblicial cord blood: Counselling, collection, and banking’, Journal of Obstetrics and Gynecology Canada, no. 328, pp. 832-844.
Barker, JN, Scaradavou, A & Stevens, CE, 2010, ‘Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies’, Blood, vol. 115, no. 9, pp. 1843-1849.
Gluckman, E, Rocha, V, Arcese, W, Michel, G, Sanz, G, Chan, KW, Takahashi, TA, Ortega, J, Filipovich, A, Locatelli, F, Asano, S, Fagioli, F, Vowels, M, Sirvent, A, Laporte, JP, Tiedemann, K, Amadori, S, Abecassis, M, Bordigoni, P, Diez, B, Shaw, PJ, Vora, A, Caniglia, M, Garnier, M, Ionescu, I, Garcia, J, Koegler, G, Rebulla, P, Chevret, S, Eurocord Group, 2004, ‘Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice’, Experimental Hematology, vol. 32, no. 4, pp. 397-407.
Jaime-Perez, JC, Monreal-Robles, R, Rodriguez-Romo, LN, Mancias-Guerra, C, Herrera-Garza, JL & Gomez-Almaguer, D, 2011, ‘Evaluation of volume and total nucleated cell count as cord blood selection parameters: a receiver operating characteristic curve modeling approach’, American Journal of Clinical Pathology, vol. 136, no. 5, pp. 721-726.
Manegold-Brauer, G, Borner, B, Bucher, C, Hoesli, I, Passweg, J, Girsberger, S, schoetzau, A, Gisin, S & Visca, E, 2014, ‘A prenatal prediction model for total nucleated cell count increases the efficacy of umbilical cord blood banking’, Transfusion, vol. 54, no. 11, pp. 2946-52.
Mazzocchetti, D, Bert, AM, Sartini R, Lucarini, A, Ragusa, G, Caroli M & Pierelli, L, 2014, ‘Totally nucleated cells as a sole predictor of distinct targets of hematopoietic potential (CD34+ cells) in cord blood units: the results of a large series analysis in autologous cord blood units”, Transfusion, vol. 54, no. 2, pp. 1256-1262.